stromectol 3mg, containing ivermectin, has been explored for its potential as a prophylactic agent against parasitic infections in high-risk populations, such as migrant workers and refugees. By administering preventive treatment to vulnerable groups living in crowded and unsanitary conditions, it helps reduce the risk of disease transmission and alleviate the burden of parasitic infections.